Kimberly Palangio, DO
Epilepsy · Lawrenceville, NJNPI 1427218429
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 151 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 64.7% of it on its own, with 16 other manufacturers making up the rest. 2025 is the largest year on record at $541, 6.4 times the $85 reported in 2019.
Across 151 payments — averaging $11.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novartis$140
- EMD Serono, Inc.$97
- Eisai Inc.$57
- AstraZeneca$54
- Boston Scientific$36
- plus $240 from 11 others
What the payments were for
- Food & beverage$1,75999%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 116 | $1,146 |
| Novartis | 8 | $140 |
| EMD Serono, Inc. | 7 | $97 |
| Eisai Inc. | 3 | $57 |
| AstraZeneca(2 entities) | 3 | $54 |
| Boston Scientific | 1 | $36 |
| Globus Medical | 1 | $35 |
| Argenx US, Inc. | 2 | $34 |
| Johnson & Johnson | 1 | $29 |
| Pfizer | 1 | $25 |
| Sunovion Pharmaceuticals Inc. | 2 | $24 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| Biogen | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| Greenwich Biosciences, Inc. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
| Almatica Pharma LLC | 1 | $12 |
How this compares
Too few epilepsy providers in New Jerseyto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 83 | $86,935 |
| BriviactBrivaracetam | 34 | $65,472 |
| QuliptaAtogepant | 47 | $61,801 |
| Emgality PenGalcanezumab-Gnlm | 47 | $53,303 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 45 | $52,407 |
| RytaryCarbidopa/Levodopa | 18 | $52,347 |
| Nurtec OdtRimegepant Sulfate | 47 | $48,753 |
| AptiomEslicarbazepine Acetate | 15 | $42,837 |
| NuedextaDextromethorphan Hbr/Quinidine | 23 | $40,902 |
| Memantine Hcl ErMemantine Hcl | 311 | $32,755 |
| BotoxOnabotulinumtoxina | 23 | $29,615 |
| Aimovig AutoinjectorErenumab-Aooe | 27 | $28,646 |
| Lamotrigine ErLamotrigine | 41 | $14,526 |
| TrileptalOxcarbazepine | 12 | $14,161 |
| Ajovy SyringeFremanezumab-Vfrm | 13 | $9,345 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta, Botox | $1,146 | $178,351153 claims |
| PfizerNurtec Odt | $25 | $48,75347 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $24 | $42,83715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few epilepsy providers in New Jerseyon file to place this against a meaningful peer group, so we don't.
Other epilepsy in Lawrenceville
- Aissa AlexeevaLawrenceville$3K
- Manuel VergaraLawrenceville$3K
- Nicole HartmannLawrenceville$3K
- Breynn EntwistleMarlboro$4K
- Olga AlexeevaMorristown$2K
- Alma YumSummit$2K
- Palak PatelEdison$1K
- Stephen WongSummit$871
- Stefan GillenPompton Plains$871
- Helen HanNew Brunswick$52
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.